Rating Change
UBS analysts reiterated a Neutral rating on Insulet Corporation (NASDAQ:PODD) on August 06, 2026.
reiterateNASDAQ:PODD
UBS Reiterates Neutral Rating on Insulet Corporation (PODD)
Rating Change UBS analysts reiterated a Neutral rating on Insulet Corporation (NASDAQ:PODD) on August 06, 2026. Market Context Insulet Corporation operates in the Healthcare…
Market Context
Insulet Corporation operates in the Healthcare sector. The stock currently trades at $139.30 with a market capitalization of $20.7B. The stock has declined 57.4% over the past 52 weeks.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Insulet Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Insulet Corporation
Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 06, 2026 | Leerink Partners | Market Perform | N/A |
| Aug 06, 2026 | Benchmark | Buy | N/A |
| Aug 06, 2026 | Bernstein | Outperform | N/A |
| Aug 06, 2026 | RBC Capital | Outperform | N/A |
| Aug 06, 2026 | UBS | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View PODD Stock Page
Frequently Asked Questions
What does a Neutral rating mean for PODD?
A Neutral rating from UBS reflects the analyst's outlook on Insulet Corporation (NASDAQ:PODD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PODD forecast page.
